EW vs HALO: fair value comparison
Edwards Lifesciences Corporation and Halozyme Therapeutics, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our ranking by discount to fair value.
| EW | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $85.21 | $121.84 |
| 12-month range | $75.87–$95.18 | $61.63–$121.84 |
| Rank by discount to fair value | #33 of 108 Healthcare | #32 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | High |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: EW fair value analysis · HALO fair value analysis